{"id":3633,"date":"2023-06-16T08:00:00","date_gmt":"2023-06-16T05:00:00","guid":{"rendered":"https:\/\/tatd.org.tr\/toksikoloji\/?p=3633"},"modified":"2023-06-13T19:15:15","modified_gmt":"2023-06-13T16:15:15","slug":"yilan-akrep-antivenom","status":"publish","type":"post","link":"https:\/\/tatd.org.tr\/toksikoloji\/2023\/06\/16\/yilan-akrep-antivenom\/","title":{"rendered":"Do\u011fa Uyan\u0131yor, Y\u0131lan Is\u0131rmalar\u0131 ve Akrep Sokmalar\u0131nda G\u00fcncel Tedavi, Antivenom Uygulamalar\u0131"},"content":{"rendered":"\n<p><strong>YILAN ISIRMALARI<\/strong><\/p>\n\n\n\n<p><strong>Olgu<\/strong><\/p>\n\n\n\n<p>Haziran da geldi. Tatil planlar\u0131 yap\u0131lmaya ba\u015fland\u0131 m\u0131? Otel tatili mi, do\u011fa tatili mi? Yurt i\u00e7i mi, yurt d\u0131\u015f\u0131 m\u0131? Neyse 112 ambulans\u0131 geldi; planlar biraz daha bekleyebilir \ud83d\ude41<\/p>\n\n\n\n<p>-\u2018Ne getirdiniz arkada\u015flar?\u2019<\/p>\n\n\n\n<p>-\u2018Hocam Wulingyuan il\u00e7e hastanesinden geliyoruz, 39 ya\u015f, erkek hasta, \u00f6zge\u00e7mi\u015finde \u00f6zellik yok. \u00d6n tan\u0131m\u0131z; Non-ST MI, senkop\u2019,<\/p>\n\n\n\n<p>-\u2018Hastan\u0131n baca\u011f\u0131 niye mor? (Resim 1)<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"850\" height=\"714\" src=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/307bf44144f755d03aae748e8add78d6.jpeg\" alt=\"\" class=\"wp-image-3635\" srcset=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/307bf44144f755d03aae748e8add78d6.jpeg 850w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/307bf44144f755d03aae748e8add78d6-300x252.jpeg 300w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/307bf44144f755d03aae748e8add78d6-768x645.jpeg 768w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/307bf44144f755d03aae748e8add78d6-750x630.jpeg 750w\" sizes=\"(max-width: 850px) 100vw, 850px\" \/><\/figure>\n<\/div>\n\n\n<p>-\u2018Hocam hastam\u0131z \u00e7oban, koyun otlat\u0131rken bay\u0131l\u0131p d\u00fc\u015fm\u00fc\u015f.\u2019<\/p>\n\n\n\n<p>Hastan\u0131n GKS: 13, TA:80\/60, Nab\u0131z: 145\/dk, O<sub>2 <\/sub>saturasyonu: % 98, Solunum say\u0131s\u0131: 22\/ dk, Kan \u015fekeri: 137 mg\/dl, EKG: Sin\u00fcs Ta\u015fikardisi. Ba\u015fvurdu\u011fu il\u00e7e hastanesinde bak\u0131lan WBC: 13.300\/uL, plt: 50.000\/uL, CKMB: 23.4 \u00b5g\/L, Hs-Trop T: 2345 ng\/L. Hastadan (al\u0131nabildi\u011fi kadar\u0131yla) ve hasta yak\u0131nlar\u0131ndan al\u0131nan anamnezde hasta da\u011fl\u0131k arazide koyunlar\u0131n\u0131 otlat\u0131rken, en son a\u011faca \u00e7\u0131kt\u0131\u011f\u0131n\u0131 hat\u0131rl\u0131yor. Yak\u0131nlar\u0131 kendisine ula\u015famay\u0131nca arazide aramaya \u00e7\u0131k\u0131yorlar. Yerde bayg\u0131n halde buluyorlar. Helikopterle da\u011fl\u0131k araziden al\u0131n\u0131p en yak\u0131n hastaneye getiriliyor. Hastaneden de acil klini\u011fimize sevk ediliyor. Bu hastan\u0131n senkopa sekonder travmas\u0131 m\u0131 geli\u015fti? Bu bacak neden bu kadar mor? Bu troponin niye y\u00fcksek? Bu trombositler neden d\u00fc\u015ft\u00fc? &#8220;<em>Babam bu kadar g\u00fczel pasta yapmay\u0131 nerden \u00f6\u011frendi<\/em> \ud83d\ude42 \ud83d\ude42 :)&#8221;<\/p>\n\n\n\n<p>T\u00fcm tomografiler normal, bacakta k\u0131r\u0131kta yok. Ama hastan\u0131n laboratuvar sonu\u00e7lar\u0131 daha k\u00f6t\u00fc: WBC: 19800 \/uL, Plt: 5000\/uL, Kreatinin: 1.77 mg\/dl, Hs Troponin T: 5333 ng\/L. Yaray\u0131 biraz daha temizleyip; \u015fu baca\u011fa biraz daha yak\u0131ndan bakay\u0131m. Tibian\u0131n hemen \u00f6n y\u00fcz\u00fcnde cillteki di\u015f izine benzeyen lezyonda ne? (Resim 1-2)<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" width=\"469\" height=\"466\" src=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/abafc6c1a328a7f937d0a6e01ab87774.jpeg\" alt=\"\" class=\"wp-image-3634\" srcset=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/abafc6c1a328a7f937d0a6e01ab87774.jpeg 469w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/abafc6c1a328a7f937d0a6e01ab87774-300x298.jpeg 300w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/abafc6c1a328a7f937d0a6e01ab87774-150x150.jpeg 150w\" sizes=\"(max-width: 469px) 100vw, 469px\" \/><\/figure>\n<\/div>\n\n\n<p>Senkop+ Hipotansiyon+ Ta\u015fikardi+ Trombositopeni+ kreatinin ve troponin y\u00fcksekli\u011fi+ Di\u015f izi= Sherlock olmaya ne hacet olsa olsa y\u0131lan \u0131s\u0131r\u0131\u011f\u0131d\u0131r bu\u2026<\/p>\n\n\n\n<p>Bu hastan\u0131n tedavisinde ne yapmal\u0131y\u0131m?<\/p>\n\n\n\n<p>Do\u011fa m\u0131 tatili???<\/p>\n\n\n\n<p><strong>Epidemiyoloji<\/strong><\/p>\n\n\n\n<p>Y\u0131lan \u0131s\u0131r\u0131klar\u0131 bir\u00e7ok tropikal ve subtropikal \u00fclkede ihmal edilen bir halk sa\u011fl\u0131\u011f\u0131 sorunu olarak \u00f6nemini korumaya devam etmektedir D\u00fcnyada yakla\u015f\u0131k 3000 kadar y\u0131lan t\u00fcr\u00fc oldu\u011fu bilinmekte bunlar\u0131n 800\u2019 \u00fcn\u00fcn zehirli oldu\u011fu tahmin edilmektedir. T\u00fcrkiye\u2019 deki 59 y\u0131lan t\u00fcr\u00fcnden ise 17\u2019 sinin zehirli oldu\u011fu (14 <em>Viperidae<\/em>, 2 <em>Colubridae<\/em>, 1 <em>Elapadiae<\/em>) bilinmektedir. D\u00fcnya sa\u011fl\u0131k \u00f6rg\u00fct\u00fcn\u00fcn (DS\u00d6) verilerine g\u00f6re her y\u0131l yakla\u015f\u0131k 5,4 milyon y\u0131lan \u0131s\u0131r\u0131\u011f\u0131 meydana gelmekte ve bu \u0131s\u0131r\u0131klar\u0131n da 1,8-2,7 milyonu zehirlenme bulgular\u0131 g\u00f6stermektedir. 2021 y\u0131l\u0131 verilerine g\u00f6re y\u0131lan \u0131s\u0131r\u0131klar\u0131na ba\u011fl\u0131 olarak 81.410-137.880 aras\u0131nda \u00f6l\u00fcm ve yakla\u015f\u0131k \u00fc\u00e7 kat daha fazla amp\u00fctasyon ve di\u011fer kal\u0131c\u0131 sakatl\u0131klar meydana gelmi\u015ftir. T\u00fcrkiye verilerine bak\u0131ld\u0131\u011f\u0131nda; Ulusal Zehir Dan\u0131\u015fma Merkezinin 2014-2020 raporlar\u0131nda; 2018 y\u0131l\u0131nda 556, 2019 y\u0131l\u0131nda 655, 2020 y\u0131l\u0131nda ise 695 y\u0131lan \u0131s\u0131r\u0131\u011f\u0131 vakas\u0131 bildirimi yap\u0131lm\u0131\u015ft\u0131r. Bu say\u0131n\u0131n tahminen daha fazla oldu\u011fu d\u00fc\u015f\u00fcn\u00fclmektedir. 2019 y\u0131l\u0131ndan itibaren Halk Sa\u011fl\u0131\u011f\u0131 M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan \u00fcretilen antivenomlar\u0131n etkinli\u011fi ve yan etki potansiyelinin takibi i\u00e7in; Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 2022 y\u0131l\u0131ndan itibaren kullan\u0131lan her antivenom i\u00e7in yaz\u0131l\u0131 bildirim de talep etmeye ba\u015flad\u0131. Bu sayede \u00f6n\u00fcm\u00fczdeki y\u0131llarda d\u00fczenlenecek raporda y\u0131lan \u0131s\u0131r\u0131klar\u0131 ile ilgili daha kesin verilere ula\u015fabilece\u011fiz.<\/p>\n\n\n\n<p><strong>Fizyopatoloji<\/strong><\/p>\n\n\n\n<p>Y\u0131lan \u0131s\u0131r\u0131klar\u0131nda klini\u011fin ortaya \u00e7\u0131kmas\u0131nda \u00f6nemli iki de\u011fi\u015fken zehrin toksik \u00f6zellikleri ve kurban\u0131n toksine g\u00f6sterdi\u011fi lokal ve sistemik yan\u0131tt\u0131r. Zehir <strong>sitotoksik, hemotoksik ve n\u00f6rotoksik<\/strong> olabilir. T\u00fcrkiye\u2019 deki zehirli y\u0131lan \u0131s\u0131r\u0131klar\u0131 (s\u0131kl\u0131kla <em>Viperidae<\/em> t\u00fcrleri) sitotoksik ve hemotoksik \u00f6zellikte kompleks yap\u0131da toksinler i\u00e7erir. Hyal\u00fcronidaz, fosfolipaz A2, asetilkolinesteraz, proteolitik enzimler (metalloproteinaz), kollajenaz, serotonin, histamin, prokoag\u00fclanlar, antikoagulanlar ve hemotoksinler; subkutan yap\u0131larda ve kapiller endotelinde hasar meydana getirirler. <strong>Hemoliz ve koag\u00fclopatiye <\/strong>neden olurlar. N\u00f6rotoksisite \u00e7ok az say\u0131da olup, Elapidae (Kral Kobra) t\u00fcr\u00fc y\u0131lan \u0131s\u0131r\u0131klar\u0131nda g\u00f6r\u00fcl\u00fcr. N\u00f6rotoksin n\u00f6romusk\u00fcler bile\u015fkede sinaptik n\u00f6ronal asetilkolin resept\u00f6rlerine ba\u011flanarak n\u00f6romusk\u00fcler ge\u00e7i\u015fi engeller. \u00d6l\u00fcm s\u0131kl\u0131kla h\u0131zla geli\u015fen diafragma paralizisine ba\u011fl\u0131 geli\u015fir.<\/p>\n\n\n\n<p><strong>Zehirli Y\u0131lanlar\u0131n Tan\u0131mlanmas\u0131<\/strong><\/p>\n\n\n\n<p>Kimi zaman su \u015fi\u015fesi i\u00e7inde, kimi zaman siyah bakkal po\u015fetinde; \u00f6ld\u00fcr\u00fclerek veya ba\u015f\u0131 kopar\u0131larak su\u00e7luyu te\u015fhis etmek ya da acil servislerimizin arka taraf\u0131ndaki b\u00fcy\u00fck laboratuvarlarda (!) panzehir yap\u0131lmas\u0131 beklentisi ile getirilir olay\u0131n failleri. \u00dcstelik yeniden \u0131s\u0131r\u0131lma riskini g\u00f6ze alarak. Peki nas\u0131l te\u015fhis edilir zehirli y\u0131lanlar? Zehirli y\u0131lanlarda g\u00f6rmeyi destekleyen \u0131s\u0131ya duyarl\u0131 \u00e7ukurcuklar (pit) burun ile g\u00f6z aras\u0131nda yer al\u0131r. Pupilleri eliptik (vertikal) olup, kafalar\u0131 daha belirgin olarak \u00fc\u00e7gen \u015feklindedir. Is\u0131rd\u0131klar\u0131nda kan s\u0131z\u0131nt\u0131s\u0131na neden olan 2 adet kavisli sivri maksiller di\u015fleri vard\u0131r. Zehirli y\u0131lanlar\u0131n ventral y\u00fcz\u00fcnde anal tabakadan kuyru\u011fa kadar olan k\u0131s\u0131mda tek s\u0131ra pul veya plaklar mevcutken, zehirsiz olanlarda bu pullar \u00e7ift s\u0131ra olarak devam eder.<\/p>\n\n\n\n<p><strong>Klinik<\/strong><\/p>\n\n\n\n<p>Y\u0131lan \u0131s\u0131r\u0131klar\u0131na ba\u011fl\u0131 lokal ve sistemik bulgular g\u00f6r\u00fclebilir. Is\u0131r\u0131klar\u0131n y\u00fczde %20\u2019 si kuru \u0131s\u0131r\u0131klard\u0131r. Yani y\u0131lanlar di\u015flerini cilde ge\u00e7irebilmi\u015f ancak zehri bo\u015faltacak zamanlar\u0131 olmam\u0131\u015ft\u0131r. Ancak zehrin bo\u015fald\u0131\u011f\u0131 \u0131s\u0131r\u0131klarda; dakikalar ve saatler sonras\u0131nda \u0131s\u0131r\u0131k yerinde kanamal\u0131 di\u015f izi, ekimoz, hemorajik b\u00fcl, \u0131s\u0131r\u0131k yerinden proksimale do\u011fru ilerleyen \u00f6dem, a\u011fr\u0131, sel\u00fclit, cilt nekrozu ve kompartman sendromu g\u00f6r\u00fclebilir.<\/p>\n\n\n\n<p>Sistemik bulgular ise t\u00fcm organ sistemlerini etkileyebilir. Ba\u015flang\u0131\u00e7ta halsizlik, g\u00fc\u00e7s\u00fczl\u00fck, terleme, bulant\u0131, kusma, kar\u0131n a\u011fr\u0131s\u0131 gibi <strong>nonspesifik semptomlar<\/strong> g\u00f6r\u00fclebilir. Sonras\u0131nda;&nbsp;<\/p>\n\n\n\n<p><strong>Kardiyovask\u00fcler sistem anormallikleri<\/strong> (nefes darl\u0131\u011f\u0131, \u00e7arp\u0131nt\u0131, EKG De\u011fi\u015fiklikleri, akci\u011fer \u00f6demi, \u015fok bulgular\u0131, ta\u015fikardi, hipotansiyon)<\/p>\n\n\n\n<p><strong>Kanama diatezi bulgular\u0131<\/strong> (pete\u015fi, burun kanamas\u0131, di\u015feti kanamas\u0131, intravask\u00fcler hemoliz, Dissemine intravask\u00fcler koag\u00fclopati (D\u0130K) ) (<em>Viperidae<\/em> t\u00fcrlerine ba\u011fl\u0131)<\/p>\n\n\n\n<p><strong>N\u00f6rolojik Bulgular<\/strong> (konu\u015fma bozuklu\u011fu, parestezi, \u00e7ift g\u00f6rme, pitoz, fasik\u00fclasyon, solunum felci, kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fc, \u015fuur bozuklu\u011fu (<em>Elapadiae <\/em>t\u00fcrlerine ba\u011fl\u0131)<\/p>\n\n\n\n<p><strong>Rabdomiyoliz <\/strong>(ciddi kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fc, myoglob\u00fclin\u00fcri, hipovolemi, Akut B\u00f6brek Yetersizli\u011fi) g\u00f6r\u00fclebilir.<\/p>\n\n\n\n<p><strong>Tedavi<\/strong><\/p>\n\n\n\n<p>Eski M\u0131s\u0131r\u2019 da <strong>\u201c\u015feytani ruhlar\u0131n \u00e7\u0131kmas\u0131\u201d<\/strong> i\u00e7in yara yerine insizyon uygulan\u0131rken, 1362-1652 y\u0131llar\u0131 aras\u0131nda d\u0131\u015f g\u00f6r\u00fcn\u00fcm\u00fcn\u00fcn bir y\u0131lan\u0131n derisine benzemesi sebebiyle <strong>y\u0131lan ta\u015f\u0131 (snake<\/strong> <strong>stone)<\/strong> suda bekletilip suyu panzehir olarak kurbanlara i\u00e7irilmi\u015f. 1900\u2019 l\u00fc y\u0131llar\u0131n ba\u015f\u0131nda antidot olarak <strong>\u201cviski\u201d <\/strong>kullan\u0131lm\u0131\u015f.<strong>1954 <\/strong>y\u0131l\u0131nda <strong>ilk modern y\u0131lan antiserumu <\/strong>ABD\u2019 de Wyeth laboratuvarlar\u0131nda \u00fcretilene kadar da;<strong>karboksilik asitten, striknine, koterizasyon, elektro\u015foktan, gaita ve idrara <\/strong>kadar t\u00fcrl\u00fc \u00e7areler denenmi\u015f.<\/p>\n\n\n\n<p>Y\u0131lan \u0131s\u0131r\u0131klar\u0131n\u0131n tedavisi alanda yap\u0131lan ilk yard\u0131m uygulamalar\u0131 ve hastanede yap\u0131lan tedavi olmak \u00fczere 2 b\u00f6l\u00fcme ayr\u0131l\u0131r.<\/p>\n\n\n\n<p><strong>Alanda Tedavi<\/strong><\/p>\n\n\n\n<p>Olay yeri m\u00fcdahalesinde; m\u00fccadelemiz hem y\u0131lan zehriyle hem de Ye\u015fil\u00e7amla asl\u0131nda. Hastaya ve getiren yak\u0131nlar\u0131na t\u00fcm C\u00fcneyt Ark\u0131n filmlerinde g\u00f6rd\u00fc\u011f\u00fc emme, ba\u011flama, kesme, toprak basma i\u015flemlerini kesinlikle bir daha yapmamas\u0131n\u0131 s\u00f6yl\u00fcyoruz. Turnike, insizyon, eksizyon, amp\u00fctasyon, elektro\u015fok, koterizasyon, buz uygulamas\u0131, vakumla, \u015f\u0131r\u0131ngayla, a\u011f\u0131zla emme gibi y\u00f6ntemler zehrin emilimin artmas\u0131na, yara yerinin kanamas\u0131na ve enfekte olmas\u0131na neden olaca\u011f\u0131ndan kesinlikle uygulanmamal\u0131d\u0131r.<\/p>\n\n\n\n<p>Hasta sakinle\u015ftirilerek olay yerinden uzakla\u015ft\u0131r\u0131lmal\u0131, \u0131s\u0131r\u0131lm\u0131\u015f k\u0131s\u0131m hareketsiz hale getirilip, kalp seviyesinin \u00fcst\u00fcnde tutulmas\u0131 sa\u011flanmal\u0131d\u0131r. Hastan\u0131n en az hareket etmesi tavsiye edilir. (Y\u0131lan\u0131n pe\u015finden ko\u015fmak, yakalamaya \u00e7al\u0131\u015fmak m\u00fckerrer \u0131s\u0131r\u0131klara ve yara yerinin kanlan\u0131p zehrin yay\u0131lmas\u0131na neden olur, kesinlikle yap\u0131lmamal\u0131d\u0131r) Is\u0131r\u0131k b\u00f6lgesinde turnike yapabilecek, saat, y\u00fcz\u00fck, bilezik, tak\u0131 ve s\u0131k\u0131 k\u0131yafetler varsa erken d\u00f6nemde \u00e7\u0131kar\u0131lmal\u0131d\u0131r. Alanda ama\u00e7 hastaya zarar vermeden en yak\u0131n sa\u011fl\u0131k kurulu\u015funa ula\u015fmas\u0131n\u0131 sa\u011flamakt\u0131r.&nbsp;<\/p>\n\n\n\n<p><strong>Yara Bak\u0131m\u0131 ve \u0130lk Yard\u0131m<\/strong><\/p>\n\n\n\n<p>Y\u0131lan \u0131s\u0131r\u0131\u011f\u0131 ile gelen her hastada \u00f6ncelikli olarak hava yolu, solunum ve dola\u015f\u0131m kontrol\u00fc yap\u0131lmal\u0131d\u0131r. Hasta g\u00fcvenlik \u00e7emberine al\u0131n\u0131p; damar yolu a\u00e7\u0131l\u0131p (laboratuvar testleri i\u00e7in kan al\u0131nmal\u0131: tam kan say\u0131m\u0131, koag\u00fclasyon parametreleri (PTZ, APTT, fibrinojen), serum elektrolitleri, \u00fcre, kreatinin, laktat dehidrogenaz, kreatinin fosfokinaz, bilirubin seviyeleri, karaci\u011fer fonksiyon testleri ve ayr\u0131ca tam idrar tetkiki), monitorizasyonu sa\u011flan\u0131p, oksijen ihtiyac\u0131 varsa (O<sub>2<\/sub> Sat&lt;%94) oksijen ba\u015flanmal\u0131d\u0131r. Sonras\u0131nda h\u0131zl\u0131 bir \u00f6yk\u00fc al\u0131nmal\u0131d\u0131r. Is\u0131r\u0131lma zaman\u0131, uygulanan ilk yard\u0131m giri\u015fimleri, komorbiditeleri, ila\u00e7 alerjileri ve antivenom uygulan\u0131p uygulanmad\u0131\u011f\u0131 sorulmal\u0131d\u0131r.<\/p>\n\n\n\n<p>Yara yerinde muayenesinde di\u015f izleri, \u00f6dem eritem, ekimoz ve hemorajik b\u00fcller kay\u0131t alt\u0131na al\u0131nmal\u0131d\u0131r. Yara yeri nemli gazl\u0131 bez ile silinmelidir. \u0130lgili b\u00f6lge <strong>immobil<\/strong> hale getirilmelidir. Hastalar genellikle buna uymakta zorland\u0131\u011f\u0131 i\u00e7in <strong>atel uygulamas\u0131<\/strong> yap\u0131labilir. Yap\u0131lacak atel \u0131s\u0131r\u0131k yerini ve proksimalini muayene etmeye izin verecek ve lenfatik drenaj\u0131 bozmayacak \u015fekilde gev\u015fek yap\u0131lmal\u0131d\u0131r. Atel sayesinde; ekstremite hareketleri engellenerek lenfatik dola\u015f\u0131m ile zehrin yay\u0131lmas\u0131 engellenir. Ayr\u0131ca iskelet kaslar\u0131 hareketsiz hale getirerek dola\u015f\u0131m\u0131n yava\u015flamas\u0131 sa\u011flan\u0131r. Is\u0131r\u0131k ve \u00f6dem yeri takip ama\u00e7l\u0131 <strong>i\u015faretlenmelidir. <\/strong>Antivenom tedavi ihtiyac\u0131n\u0131 belirlemede ve tedaviye yan\u0131t\u0131 de\u011ferlendirmede bu i\u015faretlemeler yard\u0131mc\u0131d\u0131r.<strong> Tetanoz proflasisi <\/strong>yap\u0131lmal\u0131d\u0131r. <strong>Antibiyotik proflaksisi <\/strong>sadece kesme, emme i\u015flemi yap\u0131lan kirli yaralar i\u00e7in \u00f6nerilir, rutin \u00f6nerilmez.<\/p>\n\n\n\n<p><strong>Ne Zaman Antivenom Tedavi Verelim?<\/strong><\/p>\n\n\n\n<p>DS\u00d6 2016 y\u0131l\u0131nda yay\u0131nlad\u0131\u011f\u0131 y\u0131lan \u0131s\u0131r\u0131klar\u0131 rehberinde antivenom tedaviyi hem lokal hem de sistemik zehirlenme bulgular\u0131nda \u00f6nermektedir. Buna g\u00f6re;<\/p>\n\n\n\n<p><strong>Lokal Zehirlenme Bulgular\u0131<\/strong><\/p>\n\n\n\n<p>-Is\u0131r\u0131ktan sonraki ilk 48 saatte \u0131s\u0131r\u0131lan ekstremitenin yar\u0131s\u0131na kadar olan \u015fi\u015flik<\/p>\n\n\n\n<p>-Parmak \u0131s\u0131r\u0131klar\u0131ndan sonraki \u015fi\u015flik<\/p>\n\n\n\n<p>-Is\u0131r\u0131ktan birka\u00e7 saat sonra \u00f6dem yerinin eklem atlamas\u0131<\/p>\n\n\n\n<p>-Is\u0131r\u0131lan ekstremitede lenfadenopati<\/p>\n\n\n\n<p><strong>Sistemik Zehirlenme Bulgular\u0131<\/strong><\/p>\n\n\n\n<p><strong>-Hemostatik bozukluk: <\/strong>Spontan sistemik kanama, trombositopeni, INR&gt;1.2, PTZ&gt;18-19 sn<\/p>\n\n\n\n<p><strong>-N\u00f6rotoksisite: <\/strong>Pitozis, external oftalmopleji, paralizi<\/p>\n\n\n\n<p><strong>-Kardiyovask\u00fcler anormallikler: <\/strong>Hipotansiyon, \u015fok, kardiyak aritmi<\/p>\n\n\n\n<p><strong>-ABY: <\/strong>Oligo\u00fcri, an\u00fcri, kreatinin y\u00fcksekli\u011fi, hemoglobin\u00fcri, myoglobin\u00fcri<\/p>\n\n\n\n<p><strong>-\u0130ntravask\u00fcler hemoliz, Rabdomyoliz<\/strong><\/p>\n\n\n\n<p>varl\u0131\u011f\u0131nda antivenom tedavi verilebilir.<\/p>\n\n\n\n<p>\u00dclkemizde Halk Sa\u011fl\u0131\u011f\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan \u00fcretilen 3 y\u0131lan t\u00fcr\u00fcne <strong>(<em>Macrovipera lebetina<\/em> (Koca Engerek). <em>Montivipera xanthina <\/em>(\u015eeritli Engerek), <em>Vipera ammodytes <\/em>(Boynuzlu Engerek)<em>) <\/em><\/strong>kar\u015f\u0131 antivenom i\u00e7eren <strong>Polivalan Y\u0131lan Antivenomu<\/strong> (1 vial=10 ml) bulunmaktad\u0131r.<\/p>\n\n\n\n<p><strong>Ne Kadar Antivenom Verelim?<\/strong><\/p>\n\n\n\n<p>Genellikle, antivenomlar\u0131n prospekt\u00fcs\u00fcnde belirtilen dozajlar, laboratuvar faresi LD50\u2018 lerine ve ED50\u2018 lerine dayan\u0131r ve klinik g\u00fcvenilirli\u011fi insanlar i\u00e7in d\u00fc\u015f\u00fck d\u00fczeydedir. (Tablo 1) Hasta geldi\u011finde klinik evrelemesi yap\u0131lmal\u0131, geli\u015f ve takip evresine g\u00f6re verilecek antivenom dozuna karar verilmelidir. (Tablo 2) Daha y\u00fcksek bir ba\u015flang\u0131\u00e7 (y\u00fckleme) dozuna dayal\u0131 rejimler, birka\u00e7 g\u00fcn boyunca tekrarlanan d\u00fc\u015f\u00fck dozlardan daha uygun olacakt\u0131r. Antivenom serum fizyolojik i\u00e7inde intraven\u00f6z inf\u00fczyonla ortalama 1 saat i\u00e7inde uygulanmal\u0131, alerji geli\u015febilece\u011fi unutulmamal\u0131d\u0131r. Bu nedenle antivenom tedavisi, m\u00f6nit\u00f6rize alanlarda s\u0131k\u0131 g\u00f6zlem alt\u0131nda uygulanmal\u0131d\u0131r. Verilecek vial say\u0131s\u0131 2 ila 31 vial aras\u0131nda de\u011fi\u015febilir. Hastan\u0131n klinik bulgular\u0131na ve laboratuvar parametrelerine g\u00f6re vial say\u0131s\u0131na karar vermek gerekir. \u00c7ocuklarda y\u0131lan antivenomunun dozu azalt\u0131lmamal\u0131, yeti\u015fkinlerle ayn\u0131 dozda verilmelidir. \u00c7ocuklar\u0131n beden kitle indeksi d\u00fc\u015f\u00fck oldu\u011fundan daha \u015fiddetli zehirlenme tablolar\u0131 ortaya \u00e7\u0131kmaktad\u0131r. Antivenom tedavinin gebelik kategorisi C\u2019 dir Antivenom zehirlenme bulgusu olan gebe hastalarda evrelemeye g\u00f6re verilmelidir. \u00c7\u00fcnk\u00fc y\u0131lan zehirine ba\u011fl\u0131 ortaya \u00e7\u0131kacak trombositopeni ve D\u0130K bebek ve anne \u00f6l\u00fcm\u00fcne sebebiyet verebilmektedir.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" width=\"650\" height=\"388\" src=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-2.png\" alt=\"\" class=\"wp-image-3639\" srcset=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-2.png 650w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-2-300x179.png 300w\" sizes=\"(max-width: 650px) 100vw, 650px\" \/><figcaption class=\"wp-element-caption\"><strong>Tablo 1: <\/strong>Polivalan tip antivenom i\u00e7in \u00f6nerilen doz (Prospekt\u00fcs bilgisi)<\/figcaption><\/figure>\n<\/div>\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"654\" height=\"692\" src=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-1.png\" alt=\"\" class=\"wp-image-3637\" srcset=\"https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-1.png 654w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-1-284x300.png 284w, https:\/\/tatd.org.tr\/toksikoloji\/wp-content\/uploads\/sites\/6\/2023\/06\/78805a221a988e79ef3f42d7c5bfd418-1-595x630.png 595w\" sizes=\"(max-width: 654px) 100vw, 654px\" \/><figcaption class=\"wp-element-caption\"><strong>Tablo 2: <\/strong>Riley BD, Pizon AF, Ruha AM. Snakes and other reptiles. In: Goldfrank LR, editor. Goldfrank&#8217;s toxicologic emergencies. Stamford (Conn): Appleton &amp; Lange, 11 edth 2019. p. 1620.<\/figcaption><\/figure>\n<\/div>\n\n\n<p><strong>Kan ve kan \u00fcr\u00fcnleri<\/strong><\/p>\n\n\n\n<p>Y\u0131lan zehrinin i\u00e7erdi\u011fi fosfolipazlar trombosit membran hasar\u0131 yaparak trombositopeni yapabilir. Ayr\u0131ca trombosit agregasyonu da trombositopeniye neden olabilir. Y\u0131lan \u0131s\u0131r\u0131klar\u0131na ba\u011fl\u0131 ortaya \u00e7\u0131kan koag\u00fclopati ve trombositopenide antivenom tedavi vermeden, kan \u00fcr\u00fcnlerinin verilmesi dola\u015f\u0131mda bulunan venom taraf\u0131ndan yeni bir resept\u00f6r olarak alg\u0131lan\u0131r ve mevcut koag\u00fclopatiyi k\u00f6t\u00fcle\u015ftirebilir. Ancak hayat\u0131 tehdit eden kanamas\u0131 olan hastalarda, kompartman sendromuna gidi\u015fat\u0131 olan hastalarda ve ciddi sistemik bulgular\u0131 olan hastalarda antivenom tedavi ile beraber kan \u00fcr\u00fcnlerinin (TDP, trombosit, eritrosit s\u00fcspansiyonu ve kriyopresipitat) verilmesi d\u00fc\u015f\u00fcn\u00fclebilir.<\/p>\n\n\n\n<p><strong>Kompartman Sendromu<\/strong><\/p>\n\n\n\n<p>Y\u0131lan zehrinin neden oldu\u011fu myonekroz kompartman sendromuna neden olabilir. Hastalarda kompartman bas\u0131nc\u0131 &gt;40 mmHg \u00fcst\u00fcnde olup, ilgili ekstremitede \u015fi\u015flik parestezi, solukluk ve pasif hareketle a\u011fr\u0131 g\u00f6r\u00fcl\u00fcr. Kompartman bas\u0131nc\u0131nda art\u0131\u015f durumunda ilgili ekstremitenin elevasyonu, ek doz antivenom ve %20\u2019 lik mannitol tedavisi (0.2g\/kg dozunda 4&#215;1) verilmelidir. Bu tedavilerin fasiyotomi ihtiyac\u0131n\u0131 azaltt\u0131\u011f\u0131 g\u00f6zlenmi\u015ftir. Bu tedaviye ra\u011fmen kompartman bas\u0131nc\u0131 d\u00fc\u015fmedi\u011finde (&gt;40 mmHg) ve dola\u015f\u0131m yetmezli\u011fine ait bulgular g\u00f6zlendi\u011finde fasiyotomi yap\u0131lmal\u0131d\u0131r. Ancak hemostatik bozukluklar; antivenom tedavi ve gerekirse kan \u00fcr\u00fcnleri ile d\u00fczeltilmeden fasiyotomi denenmemelidir.<\/p>\n\n\n\n<p><strong>Plazmaferez<\/strong><\/p>\n\n\n\n<p>\u0130lk kez Kornalik taraf\u0131ndan 1990 y\u0131l\u0131nda y\u0131lan \u0131s\u0131rmalar\u0131na ba\u011fl\u0131 zehirlenmede plazma exchange uygulanm\u0131\u015ft\u0131r. Plazmaferez plazmadaki toksinlerin uzakla\u015ft\u0131r\u0131lmas\u0131na ayr\u0131ca ekstravask\u00fcler alandaki toksinlerin redistr\u00fcbisyonuna ve eliminasyonuna yard\u0131mc\u0131 olur.<\/p>\n\n\n\n<p><strong>Optimal destek tedavi ve uygun doz antivenom tedaviye ra\u011fmen;<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ekstremitede giderek artan \u015fi\u015flik ve dola\u015f\u0131m bozuklu\u011fu<\/li>\n\n\n\n<li>Artan koag\u00fclapati durumunda<\/li>\n\n\n\n<li>N\u00f6rolojik bulgular (Ataksi, paralizi, diplopi, letarji, g\u00f6rme bozukluklar\u0131)<\/li>\n\n\n\n<li>B\u00f6brek fonksiyon testlerinde bozulma, ABY<\/li>\n\n\n\n<li>Kardiyak etkilenim (hipotansiyon, ventrik\u00fcler aritmi, miyokardit)<\/li>\n\n\n\n<li><strong>K\u00f6pr\u00fc tedavi:<\/strong> Nadir g\u00f6r\u00fclen y\u0131lan t\u00fcrlerine kar\u015f\u0131 antivenom tedavi temin edilene kadar<\/li>\n<\/ul>\n\n\n\n<p>plazmaferez y\u0131lan \u0131s\u0131r\u0131klar\u0131nda uygulanabilir.<\/p>\n\n\n\n<p><strong>Bizim hastaya ne oldu peki?&nbsp;<\/strong><\/p>\n\n\n\n<p>Is\u0131r\u0131k izini g\u00f6r\u00fcr g\u00f6rmez hastaya 3 vial antivenom 500 cc %0.9 serum fizyolojik i\u00e7inde 1 saatlik inf\u00fczyonla uyguland\u0131. \u0130lk doz antivenom inf\u00fczyonu sonras\u0131nda1. saatte; TA: 80\/60 mmHg\u2019 dan 110\/70 mmHg y\u00fckseldi, nab\u0131z: 145\/dk\u2019 dan 110\/dk\u2019 ya d\u00fc\u015ft\u00fc. 2. Saatte trombosit say\u0131s\u0131: 5000\/uL\u2019 den 35.000\/uL\u2019 e y\u00fckseldi. Hastaya takibinde sistemik ve lokal bulgular\u0131na g\u00f6re 48 saatte toplam 11 vial antivenom uyguland\u0131. \u0130kinci doz antivenom tedaviye ra\u011fmen lokal, sistemik ve laboratuvar bulgular\u0131 k\u00f6t\u00fcle\u015fen hastaya 2 \u00dcnite TDP inf\u00fczyonu yap\u0131ld\u0131. Hemoglobin de\u011ferleri 48. saatte 14.1 g\/dl\u2019 den 7.8 g\/dl gerileyen hastaya (artm\u0131\u015f Troponin ve sekonder MI nedeniyle) 1\u00dc Eritrosit s\u00fcspansiyonu transf\u00fczyonu yap\u0131ld\u0131. Yat\u0131\u015f\u0131n\u0131n 24. saatinde optimal destek tedavi, antivenom tedavi ve kan \u00fcr\u00fcnleri transf\u00fczyonuna ra\u011fmen hemoglobin 14.1 g\/dl\u2019den 8.3 g\/dl\u2019 ye, trombosit say\u0131s\u0131 35000\/IU\/L\u2019 den 5300\/IU\/L\u2019 e kreatinin de\u011feri 1.77 mg\/dl\u2019 den 2.96 mg\/dl\u2019 ye, amilaz de\u011feri 292 IU\/L\u2019den 257 IU\/L\u2019 e, troponin 5333 ng\/L&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3256 ng\/L\u2019 e de\u011fi\u015fti. Hipotansiyonu ve ta\u015fikardisi devam eden, idrar \u00e7\u0131k\u0131\u015f\u0131 azalan, laboratuvar parametreleri k\u00f6t\u00fcle\u015fen ve lokal doku \u00f6demi artan hastaya \u2018Plazmaferez\u2019 uyguland\u0131. Yat\u0131\u015f\u0131n\u0131n 7. g\u00fcn\u00fcnde laboratuvar ve klinik bulgular\u0131 d\u00fczelen hasta s\u0131hhatle taburcu edildi.<\/p>\n\n\n\n<p><strong>AKREP SOKMALARI<\/strong><\/p>\n\n\n\n<p><strong>Epidemiyoloji<\/strong><\/p>\n\n\n\n<p>G\u00fcn\u00fcm\u00fczde, d\u00fcnyada, 21 familya ve 195 cinsten olu\u015fan yakla\u015f\u0131k 2512 t\u00fcr akrep oldu\u011fu bildirilmektedir. Son y\u0131llardaki art\u0131\u015f g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda T\u00fcrkiye\u2019 de ise 4 familya ve 15 cinsten olu\u015fan yakla\u015f\u0131k 41 akrep t\u00fcr\u00fc oldu\u011fu tespit edilmi\u015ftir. T\u00fcrkiye\u2019 de bilinen en toksik akrep t\u00fcr\u00fc sistemik toksisiteye neden olan <strong><em>Leiurus quinquestriatus\u2019<\/em><\/strong>tur. Di\u011fer s\u0131k g\u00f6r\u00fclen toksik akrep t\u00fcr\u00fc <strong><em>Androctonus crassicauda<\/em><\/strong>; s\u0131kl\u0131kla G\u00fcneydo\u011fu Anadolu\u2019 da g\u00f6r\u00fcl\u00fcr ve sistemik toksisite yapar, <strong><em>Mesobuthus gibbosus<\/em><\/strong> ise s\u0131kl\u0131kla Ege B\u00f6lgesinde g\u00f6r\u00fcl\u00fcr ve lokal toksisite yapar. Ulusal Zehir Dan\u0131\u015fma Merkezinin 2014-2020 raporlar\u0131nda; 2018 y\u0131l\u0131nda 1462, 2019 y\u0131l\u0131nda 1451, 2020 y\u0131l\u0131nda ise 1729 y\u0131lan akrep sokmas\u0131 bildirimi yap\u0131lm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p><strong>Fizyopatoloji<\/strong><\/p>\n\n\n\n<p>Kompleks bir yap\u0131ya sahip akrep venomu; \u226510 n\u00f6rotoksik protein + 6 protein yap\u0131da olmayan kimyasal bile\u015fikten olu\u015fur. Akrep toksinlerinin \u00e7o\u011fu uyar\u0131labilir h\u00fccrelerin Na kanalar\u0131n\u0131n inaktivasyonu geciktirerek veya aktivasyonunu art\u0131rarak etki ederler. Bu toksinlerin baz\u0131lar\u0131 da K kanallar\u0131n\u0131 etkilemektedir. Zehir toksik etkisini artan katekolaminler yoluyla \u00f6zellikle santral sinir sistemi ve otonom sinir sisteminin hiperstim\u00fclasyonu ile g\u00f6sterir.<\/p>\n\n\n\n<p><strong>Klinik<\/strong><\/p>\n\n\n\n<p>Lokal bulgulardan sistemik zehirlenme bulgular\u0131na kadar de\u011fi\u015fik yelpazede klinik bulgulara yol a\u00e7abilir. Semptomlar genellikle akrep sokmas\u0131ndan hemen sonra ba\u015flar. Birka\u00e7 saat i\u00e7inde en y\u00fcksek seviyeye ula\u015f\u0131r. Genellikle 24-48 saat s\u00fcrer.<\/p>\n\n\n\n<p><strong>Lokal bulgu olarak; <\/strong>akrepin i\u011fnesinin girdi\u011fi yerde yan\u0131c\u0131 a\u011fr\u0131, eritem, \u015fi\u015flik, lokal doku inflamasyonu ve bazen lokal parestezi g\u00f6r\u00fclebilir.<\/p>\n\n\n\n<p><strong>Sistemik klinik bulgular;<\/strong><\/p>\n\n\n\n<p><strong>Non-spesifik bulgular: <\/strong>Hipertermi, bulant\u0131, kusma, terleme, salivasyon, bronkore<\/p>\n\n\n\n<p><strong>Kardiyovask\u00fcler anormallikler: <\/strong>Hipertansiyon, hipotansiyon, ta\u015fikardi, bradikardi, myokardit, \u015fok<strong>, <\/strong>pulmoner \u00f6dem, solunum depresyonu<\/p>\n\n\n\n<p><strong>Hemostatik bozukluk: <\/strong>Koag\u00fclopati<\/p>\n\n\n\n<p><strong>N\u00f6rotoksisite: <\/strong>Kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fc, kas fasik\u00fclasyonlar\u0131, paralizi-parastezi, n\u00f6bet, ajitasyon, diplopi, nistagmus, hipereksitabilite, priapizm.<\/p>\n\n\n\n<p><strong>KL\u0130N\u0130K EVRELEME<\/strong><\/p>\n\n\n\n<p><strong>Evre 1: <\/strong>Is\u0131r\u0131lan b\u00f6lgede hafif a\u011fr\u0131 sistemik bulgu yok<\/p>\n\n\n\n<p><strong>Evre 2: <\/strong>A\u011fr\u0131n\u0131n \u00e7ok \u015fiddetli olmas\u0131 ve \u0131s\u0131r\u0131lan ekstremitenin d\u0131\u015f\u0131na ta\u015fmas\u0131, dokunmakla \u015fiddetli a\u011fr\u0131 hissedilmesi (Pozitif TAP testi)<\/p>\n\n\n\n<p><strong>Evre 3: <\/strong>N\u00f6rom\u00fcsk\u00fcler disfonksiyon veya kraniyal sinir disfonksiyon<strong><\/strong><\/p>\n\n\n\n<p>N\u00f6rom\u00fcsk\u00fcler disfonksiyon (ekstremitelerde jerkler, huzursuzluk, istem d\u0131\u015f\u0131 kas hareketleri)<\/p>\n\n\n\n<p>Kraniyal sinir disfonksiyon&nbsp;(bulan\u0131k g\u00f6rme, anormal g\u00f6z hareketleri, hipersalivasyon, dilde fasik\u00fclasyon, yutma g\u00fc\u00e7l\u00fc\u011f\u00fc, \u00fcst hava yolu disfonksiyonu, peltek konu\u015fma)<\/p>\n\n\n\n<p><strong>Evre 4: <\/strong>N\u00f6rom\u00fcsk\u00fcler disfonksiyon ve Kraniyal sinir disfonksiyon<strong><\/strong><\/p>\n\n\n\n<p>MI, pulmoner \u00f6dem, konv\u00fclziyon, \u015fok vb. bulgular\u0131n olmas\u0131<\/p>\n\n\n\n<p>Bizim \u00fclkemizde g\u00f6r\u00fclen ve sistemik toksisite yapan t\u00fcrlerde hipertansiyon, terleme, titreme, g\u00f6\u011f\u00fcs a\u011fr\u0131s\u0131 gibi bulgular daha \u00f6n plandad\u0131r.<\/p>\n\n\n\n<p><strong>Tedavi<\/strong><\/p>\n\n\n\n<p>Tedavide ama\u00e7; toksinin santral ve otonom sinir sistemi \u00fczerine olan toksik etkilerini n\u00f6tralize etmektir. Bunun i\u00e7in destek tedavi, pulmoner \u00f6dem tedavisi ve antivenom tedavi uygulan\u0131r.<\/p>\n\n\n\n<p><strong>Destek Tedavi: <\/strong>Yara yeri temizli\u011fi sa\u011flanmal\u0131; hastaya tetanoz proflaksisi ve analjezi uygulanmal\u0131d\u0131r. Sistemik analjezik tedaviye yan\u0131t al\u0131namayan \u015fiddetli lokal a\u011fr\u0131 varl\u0131\u011f\u0131nda&nbsp; %1\u2019lik ksilokain (max. 0.5 mL) ile lokal anestezi yap\u0131labilir. Hipertermi i\u00e7in so\u011fuk uygulama ve parastemol verilebilir. Diren\u00e7li bulant\u0131-kusma tedavisinde Klorpromazin (Non selektif dopaminerjik agonist, alfa adrenerjik etki, seretonerjik ve antikolinerjik etki) ile kusmalar kontrol alt\u0131na al\u0131nmaya \u00e7al\u0131\u015f\u0131l\u0131r. S\u0131v\u0131-elektrolit, asit baz dengesi sa\u011flanmal\u0131d\u0131r. Ajitasyon ve konv\u00fclsiyonlar\u0131n kontrol\u00fcnde Fenobarbital ve diazepam \u00f6nerilir.<\/p>\n\n\n\n<p><strong>Kardiyotoksisitenin Tedavisi: <\/strong>Kardiyak bulgular artm\u0131\u015f katekolamin salg\u0131s\u0131na ve artm\u0131\u015f renin aldosteron sekresyonuna ba\u011fl\u0131 g\u00f6r\u00fcl\u00fcr.Toksin etki mekanizmas\u0131 ta\u015fiartmilere ve ileti bozukluklar\u0131na yol a\u00e7abilir. Hemodinaminin bozulmad\u0131\u011f\u0131 durumlarda m\u00fcdahale edilmeden takip \u00f6nerilmektedir. Periferik vask\u00fcler direnci azalt\u0131p, hipertansiyonun tedavisinde ACE inhibit\u00f6rleri (Kaptopril), vazodilatat\u00f6rler (Hidralazin), kalsiyum kanal blokerleri (Nifedipin) kullan\u0131labilir. Propranolol ta\u015fiaritmilerde kullan\u0131labilir ancak mortalite \u00fczerine etkisi g\u00f6sterilememi\u015ftir.<\/p>\n\n\n\n<p><strong>Pulmoner \u00d6dem Tedavisi: <\/strong>\u0130lk tercih edilecek ajan sempatolitik etkili \u03b1 adrenerjik resept\u00f6r antagonisti<strong> Prazosin (<\/strong>Minipress<sup>\u00ae<\/sup> 1, 2.5, 5 mg)\u2019 tir. <strong>&nbsp;<\/strong>Prazosinin monovalan antivenoma eklenmesi; klinik semptomlar\u0131n s\u00fcresini (terleme, salivasyon, so\u011fuk ekstremiteler, priapizm, hipertansiyon veya hipotansiyon, ta\u015fikardi), daha \u015fiddetli semptomlara d\u00f6n\u00fc\u015fmesini azalt\u0131r. Belirtiler d\u00fczelinceye kadar, oral yolla,30 \u00b5g\/kg dozunda (6 saatte bir) verilmesi \u00f6nerilir. Prazosin bulunamad\u0131\u011f\u0131nda yerine<strong>&nbsp;Dokzasosin<\/strong>&nbsp; 50 \u00b5g\/kg&nbsp;(Cardura<sup>\u00ae)<\/sup>&nbsp;kullan\u0131labilir. Afterloadu azaltmak i\u00e7in di\u00fcretik (Furosemid) tedavi verilmelidir. Kardiyojenik \u015fokta ilk tercih edilmesi gereken inotropik ajan Dobutamin (5-15 \u00b5g\/kg\/dk) olmal\u0131d\u0131r.Hastalar\u0131n invaziv ve non-invaziv (HFNCO, NIMV) mekanik ventilasyon ihtiyac\u0131 s\u0131k\u0131 takip edilmelidir.<\/p>\n\n\n\n<p><strong>Antivenom Tedavi: <\/strong>T\u00fcrkiyede <em>Androctonus crassicauda <\/em>i\u00e7in haz\u0131rlanm\u0131\u015f monovalan antivenom bulunmaktad\u0131r. Antivenom tedaviye ba\u011fl\u0131 serum hastal\u0131\u011f\u0131 ve anaflaksi riski olmas\u0131 sebebiyle; ciddi sistemik bulgu geli\u015fen hastalara antivenom tedavi \u00f6nerilir. Ancak 6 ya\u015f\u0131ndan k\u00fc\u00e7\u00fck hastalarda (mortalite y\u00fcksek) ve 65 ya\u015f\u0131ndan b\u00fcy\u00fck hastalarda (e\u015flik eden komorbiditeler nedeniyle) akrep sokmalar\u0131nda toksik etki potansiyeli y\u00fcksektir. Bu hastalarda sistemik bulgu geli\u015fmesi beklenmeden antivenom tedavi verilmesi \u00f6nerilir. 1 vial antivenom serum fizyolojik i\u00e7inde 30 dakikal\u0131k intraven\u00f6z inf\u00fczyonla verilmelidir. Antivenom tedavi mutlaka olas\u0131 bir anaflaktoid reaksiyon i\u00e7in gerekli ila\u00e7 ve malzeme haz\u0131rl\u0131klar\u0131 yap\u0131larak ve hastalar monitorize edilerek verilmelidir. Antivenom uygulamas\u0131n\u0131n yan etki s\u0131kl\u0131\u011f\u0131 %1.6-6.6 aras\u0131ndad\u0131r.&nbsp; En \u00f6nemli yan etkileri anafilaksi (\u00fcrtiker, anjio\u00f6dem, bronkospazm, hipotansiyon) ve serum hastal\u0131\u011f\u0131d\u0131r.<\/p>\n\n\n\n<p>_________________________<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">KAYNAKLAR<\/h2>\n\n\n\n<ol class=\"wp-block-list\" type=\"1\">\n<li><a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/snakebite-envenoming\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/snakebite-envenoming<\/a><strong><\/strong><\/li>\n\n\n\n<li>Bekta\u015f F, S\u00f6y\u00fcnc\u00fc S. (2009) Y\u0131lan Is\u0131r\u0131klar\u0131. Edit\u00f6r: Satar S. Acilde Klinik Toksikoloji. 1.Bask\u0131. Nobel T\u0131p Kitabevi, Adana ss: 593-601.<strong><\/strong><\/li>\n\n\n\n<li>Ulusal Zehir Dan\u0131\u015fma Merkezi (UZEM) Raporlar\u0131 2014-2020, <a href=\"https:\/\/hsgm.saglik.gov.tr\/depo\/kurumsal\/yayinlarimiz\/Raporlar\/Uzem\/uzem_raporlari_2014-2020.pdf\">https:\/\/hsgm.saglik.gov.tr\/depo\/kurumsal\/yayinlarimiz\/Raporlar\/Uzem\/uzem_raporlari_2014-2020.pdf<\/a><strong><\/strong><\/li>\n\n\n\n<li>Gulen M, Satar S, Yesiloglu O, Ince C, Esen CI, Acehan S. Comparison of two types of polyvalent snake antivenom used in treatment. Cukurova Med J 2020;45(3):1230-1237<strong><\/strong><\/li>\n\n\n\n<li>Bilir \u00d6. (2020) S\u00fcr\u00fcngenler. Edit\u00f6rler: Satar S, G\u00fcneysel \u00d6, Y\u00fcr\u00fcmez Y, T\u00fcredi S, Ak\u0131c\u0131 A. Klinik Toksikoloji Tan\u0131 ve Tedavi. 1.Bask\u0131. \u00c7ukurova Nobel T\u0131p Kitapevi. ss:1011-1019<\/li>\n\n\n\n<li>Warrell D. Snakebites. World Health Organization, Guidelines for the management of snakebites. 2nd Edition. WHO\/Regional Office for South-East Asia. August 2016 140 p. ISBN 978 92 9022 530 0.<\/li>\n\n\n\n<li>Le\u00f3n G, Vargas M, Segura \u00c1, Herrera M., Villalta M, S\u00e1nchez A et al Current technology for the industrial manufacture of snake antivenoms. Toxicon. 2018;151:63-73.<\/li>\n\n\n\n<li>A\u00e7ikalin A, G\u00f6kel Y, Kuvandik G, Duru M, K\u00f6seo\u011flu Z, Satar S. The efficacy of low-dose antivenom therapy on morbidity and mortality in snakebite cases. Am J Emerg Med. 2008;26:402-7.<\/li>\n\n\n\n<li>Scharman EJ, Noffsinger VD. Copperhead snakebites: Clinical severity of local effects. Ann Emerg Med. 2001;38:55-61.<\/li>\n\n\n\n<li>G\u00fcm\u00fc\u015ftekin M, Sar\u0131\u00e7oban B, G\u00fcrkan MA. Antivenomlar ve uygulama ilkeleri. Dokuz Eyl\u00fcl \u00dcniversitesi T\u0131p Fak\u00fcltesi Dergisi. 2019;34:73-83.<\/li>\n\n\n\n<li>Sarin K, Dutta KT, Vinod KV. Clinical profile &amp; complications of neurotoxic snake bite &amp; comparison of two regimens of polyvalent anti-snake venom in its treatment. Indian J Med Res. 2017;145:58-62<\/li>\n\n\n\n<li>Riley BD, Pizon AF, Ruha AM. Snakes and other reptiles. In: Goldfrank LR, editor. Goldfrank&#8217;s toxicologic emergencies. Stamford (Conn): Appleton &amp; Lange , 9 edth 2011. p. 1601-10.<\/li>\n\n\n\n<li>Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice &#8211; Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002\/jca.21705. PMID: 31180581.<\/li>\n\n\n\n<li>Zengin S, Yilmaz M, Al B, Yildirim C, Yarbil P, Kilic H, Bozkurt S, Kose A, Bayraktaroglu Z. Plasma exchange as a complementary approach to snake bite treatment: an academic emergency department&#8217;s experiences. Transfus Apher Sci. 2013 Dec;49(3):494-8. doi: 10.1016\/j.transci.2013.03.006. Epub 2013 Mar 30. PMID: 23545384.<\/li>\n\n\n\n<li>Isbister GK, Bawaskar HS. Scorpion envenomation. N Engl J Med. 2014 Jul 31;371(5):457-63. doi: 10.1056\/NEJMra1401108. PMID: 25075837.<\/li>\n\n\n\n<li>Ayg\u00fcn A. (2020) Artropodlar: Zar Kanatl\u0131lar-Akrepler-\u00d6r\u00fcmcekler. Edit\u00f6rler: Satar S, G\u00fcneysel \u00d6, Y\u00fcr\u00fcmez Y, T\u00fcredi S, Ak\u0131c\u0131 A. Klinik Toksikoloji Tan\u0131 ve Tedavi 1. Bask\u0131. \u00c7ukurova Nobel T\u0131p Kitapevi. ss:1000-1002<\/li>\n<\/ol>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>YILAN ISIRMALARI Olgu Haziran da geldi. Tatil planlar\u0131 yap\u0131lmaya ba\u015fland\u0131 m\u0131? Otel tatili mi, do\u011fa tatili mi? Yurt i\u00e7i mi, yurt d\u0131\u015f\u0131&hellip;<\/p>\n","protected":false},"author":3242,"featured_media":3638,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[10014,10019],"tags":[36,10022,406,444,449],"class_list":["post-3633","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-akademik-blog-yazisi","category-tft","tag-akrep","tag-tft","tag-toksikoloji","tag-yilan","tag-zehirlenme"],"acf":[],"_links":{"self":[{"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/posts\/3633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/users\/3242"}],"replies":[{"embeddable":true,"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/comments?post=3633"}],"version-history":[{"count":0,"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/posts\/3633\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/media\/3638"}],"wp:attachment":[{"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/media?parent=3633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/categories?post=3633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tatd.org.tr\/toksikoloji\/wp-json\/wp\/v2\/tags?post=3633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}